12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Merus Labs International, POA Pharma Scandinavia AB, Proximum d.o.o., SPCare Lda sales and marketing update

Merus granted exclusive commercialization and distribution rights for Emselex darifenacin to POA Pharma in Denmark, Norway, Sweden, Finland and Iceland, Proximum in Croatia and SPCare in Portugal. The muscarinic acetylcholine receptor M3 (...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >